SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

被引：0

作者：

Qin, Shuqui ^{[1
]}

Li, Jin ^{[2
]}

Zhou, Aiping ^{[3
]}

Zhang, Yanqiao ^{[4
]}

Yuan, Xianglin ^{[5
]}

Zhu, Liangjun ^{[6
]}

Qin, Baoli ^{[7
]}

Zeng, Shan ^{[8
]}

Shen, Lin ^{[9
]}

Yuan, Ying ^{[10
]}

Wang, Weibo ^{[11
]}

Liang, Jun ^{[12
]}

Zhang, Xianwen ^{[13
]}

Ye, Feng ^{[14
]}

Chen, Ping ^{[15
]}

Wang, Huaizhang ^{[16
]}

Yu, Zhenyan ^{[17
]}

Yue, Lu ^{[18
]}

Fang, Yong ^{[19
]}

Xiong, Jianping ^{[20
]}

Yang, Jianwei ^{[21
]}

Wan, Yiye ^{[22
]}

Yin, Xianli ^{[23
]}

Wang, Wenling ^{[24
]}

Xu, Nong ^{[25
]}

Wang, Xiaohong ^{[26
]}

Xiao, Zemin ^{[27
]}

Su, Huafang ^{[28
]}

Wang, Ying ^{[29
]}

Gu, Kangsheng ^{[30
]}

Tu, Shuiping ^{[31
]}

Wang, Zishu ^{[32
]}

Liu, Bo ^{[33
]}

Hu, Xiaohua ^{[34
]}

Liu, Weixian ^{[35
]}

Li, Xiaofeng ^{[36
]}

机构：

[1] Nanjing Jiangning Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China

[2] Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China

[3] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[4] Harbin Med Univ, Canc Hosp, Dept Pathol, Harbin, Heilongjiang, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, R China, Wuhan, Hubei, Peoples R China

[6] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[7] Liaoning Canc Hosp & Inst, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China

[8] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China

[9] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[11] Shandong Prov Hosp, Dept Chemotherapy, Jinan, Peoples R China

[12] Peking Univ, Int Hosp, Dept Med Oncol, Beijing, Peoples R China

[13] Northern Jiangsu Peoples Hosp, Dept Med Oncol, Yangzhou, Jiangsu, Peoples R China

[14] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China

[15] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China

[16] Henan Canc Hosp, Dept Integrated Chinese & Western Med, Zhengzhou, Henan, Peoples R China

[17] Mudanjiang Tumor Hosp, Dept Med Oncol, Mudanjiang, Heilongjiang, Peoples R China

[18] Qingdao Municipal Hosp Grp, Dept Oncol, Qingdao, Shandong, Peoples R China

[19] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Jiangxi, Peoples R China

[21] Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Fujian, Peoples R China

[22] Jiangxi Canc Hosp, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China

[23] Cent South Univ, Canc Hosp, Xiangya Sch Med, Dept Gastroenterol & Urol, Changsha, Hunan, Peoples R China

[24] Guizhou Med Univ, Dept Abdominal Oncol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China

[25] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[26] Zhejiang Canc Hosp, Dept Abdominal Oncol, Hangzhou, Zhejiang, Peoples R China

[27] First Peoples Hosp Changde City, Dept Oncol, Changde, Hunan, Peoples R China

[28] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Wenzhou, Zhejiang, Peoples R China

[29] China Med Univ, Shengjing Hosp, Dept Med Oncol, Shenyang, Liaoning, Peoples R China

[30] Anhui Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hefei, Anhui, Peoples R China

[31] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Med Oncol, Shanghai, Peoples R China

[32] First Affiliated Hosp, Bengbu Med Coll, Dept Med Oncol, Bengbu, Anhui, Peoples R China

[33] Shandong Canc Hosp & Inst, Dept Gastroenterol, Jinan, Shandong, Peoples R China

[34] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Guangxi, Peoples R China

[35] Binzhou Peoples Hosp, Dept Med Oncol, Binzhou, Shandong, Peoples R China

[36] Quanzhou First Hosp, Dept Med Oncol, Quanzhou, Fujian, Peoples R China

来源：

CANCER COMMUNICATIONS | 2024年 / 44卷 / 08期

关键词：

D O I：

10.1002/cac2.12586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：910 / 914

页数：5

共 50 条

[41] Erlotinib (TARCEVAO) in second-line treatment of non-small cell lung cancer - A prospective, non-interventional study in german oncology practices
Tessen, H. W.
Steffen, U.
Eschenburg, H.
Steffens, C. -C.
Raacke, B. W.
ONKOLOGIE, 2008, 31 : 131 - 132
[42] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
Chu Matsuda
Michitaka Honda
Chihiro Tanaka
Ken Kondo
Takao Takahashi
Chihiro Kosugi
Yukihiko Tokunaga
Hiroyoshi Takemoto
Ho Min Kim
Junichi Sakamoto
Koji Oba
Hideyuki Mishima
Cancer Chemotherapy and Pharmacology, 2018, 81 : 1035 - 1041
[43] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
Matsuda, Chu
Honda, Michitaka
Tanaka, Chihiro
Kondo, Ken
Takahashi, Takao
Kosugi, Chihiro
Tokunaga, Yukihiko
Takemoto, Hiroyoshi
Kim, Ho Min
Sakamoto, Junichi
Oba, Koji
Mishima, Hideyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1035 - 1041
[44] Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
Sobrero, A.
Lenz, H-J.
Eng, C.
Scheithauer, W.
Middleton, G.
Chen, W.
Esser, R.
Nippgen, J.
Burris, H.
ANNALS OF ONCOLOGY, 2018, 29 : 163 - 163
[45] LLIVE: A non-interventional multicenter study of first-line Avastin® (bevacizumab) in combination with chemotherapy in patients with metastatic colorectal cancer in Lebanon
Ali, Shamseddine
Sarah, Abdel Massih
George, Chahine
Fadi, Nasr
Joseph, Kattan
Fadi, Farhat
Bassim, Kobrossy
Dany, Abi Gerges
Walid, Moukadem
Chadi, Saba
ANNALS OF ONCOLOGY, 2017, 28
[46] Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Zhu, J. L.
Li, S.
Zhu, C.
ANNALS OF ONCOLOGY, 2019, 30
[47] A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study
Satake, Hironaga
Ando, Koji
Yasui, Hisateru
Negoro, Yuji
Kinjo, Tatsuya
Yuge, Koutarou
Baba, Kenji
Orita, Hiroyuki
Hirata, Keiji
Shimokawa, Mototsugu
Makiyama, Akitaka
Saeki, Hiroshi
Oki, Eiji
Baba, Hideo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
Nobuaki Suzuki
Shoichi Hazama
Takeshi Nagasaka
Hiroaki Tanioka
Yasuo Iwamoto
Yuji Negoro
Masami Yamauchi
Michiya Kobayashi
Hiroshi Okuda
Noriaki Fujishima
Taku Nishimura
Naoki Yamanaka
Kazuhiro Toyota
Yoshiko Mori
Yuki Nakagami
Mototsugu Shimokawa
Hiroaki Nagano
Masazumi Okajima
International Journal of Clinical Oncology, 2019, 24 : 1223 - 1230
[49] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
[50] Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
Hejna, M
Köstler, WJ
Raderer, M
Tomek, S
Brodowicz, T
Scheithauer, W
Wiltschke, C
Zielinski, CC
ANTI-CANCER DRUGS, 2000, 11 (08) : 629 - 634

← 1 2 3 4 5 →